– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an...
The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26,...
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been...
AC Immune Holds Annual General Meeting of Shareholders Shareholders approved all resolutions as proposed by the Board of Directors Lausanne,...
Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of...
Delisting to take effect on July 3, 2023; Company’s common stock is expected to begin trading on the OTC under...
BURLINGTON, Mass., June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing...
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary sclerosing cholangitisSOUTH SAN FRANCISCO, Calif., June 23, 2023 (GLOBE...
Received Grant of Protection for a Design Patent in Japan Covering its Innovative LIBERTY® Robotic DriveHINGHAM, Mass., June 22, 2023...
Engages ShareIntel to Track Market Activity TARRYTOWN, NY, June 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- PaxMedica, Inc. (Nasdaq:...
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
VANCOUVER, British Columbia, June 22, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed...
UB-312 was immunogenic in patients with early Parkinson’s disease. UB-312 was generally safe and well-tolerated. Results are consistent with conclusions...
New Drug Application for arimoclomol in NPC to be filed as early as the third quarter of 2023¹EMERYVILLE, Calif., June 22,...
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based...
VYD222 has been generally well-tolerated at all dose levels, with no serious adverse events reported to dateAs predicted by pre-clinical...
BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively...
Media ReleaseCOPENHAGEN, Denmark; June 22, 2023 – Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody,...
First scientific presentation of detailed MAESTRO-NASH results confirms achievement of primary endpoints across multiple patient subgroupsNoninvasive imaging and biomarker data...